CanVasc Webinar Series
2022 ANCA Workshop Update
June 22nd, 2022 7:30-8:30pm EST
After attending this event, participants will be better able to:
-
Identify the key points presented at the EULAR conference and incorporate these into clinical practice;
-
Utilize new evidence for the management of EGPA, GPA and MPA;
-
Consider various perspectives on current controversies in any vasculitis
Christian Pagnoux, MD, MSc, MPH
Associate Professor, University of Toronto
Sinai Hospital
Toronto, ON Canada
Mats Junek, MD, MSc
Rheumatology Fellow, McMaster University
St. Joseph's Healthcare
Hamilton, ON Canada
Natasha Dehghan, MD, FRCPC
Clinical Assistant Professor, University of BC
Mary Pack Arthritis Centre
Vancouver, BC Canada
ANCA Vasculitis, Diagnostics, and Management: A personal story of more than 35 years of experience with ANCA determinations.
September 27th, 2022 7:30-8:30pm EST
After attending this event, participants will be better able to:
-
Understand the development and identification of ANCA as a biomarker (pathogenesis info);
-
Apply clinical strategies for the use of ANCA in the diagnosis and follow-up in ANCA Vasculitis;
-
Appreciate and consider new advances for the role of ANCA in the management of vasculitis
Moderated by:
Speaker:
Jan Willem Cohen Tervaert, MD, PhD
Professor, Director, Division Rheumatology
University of Alberta
Edmonton, AB Canada
Emeritus Professor of Medicine and Immunology
Maastricht University, The Netherlands
Lillian Barra, MD, MPH, FRCPC
Associate Professor
Schulich School of Medicine and Dentistry
University of Western Ontario
London, ON Canada
EULAR Recommendations for the Management of ANCA-Associated Vasculitis: 2022 Update
October 17th, 2022 12:30-1:30pm EST
After attending this event, participants will be better able to:
-
Identify the key points presented at the EULAR conference and incorporate these into clinical practice;
-
Utilize new evidence for the management of EGPA, GPA and MPA;
-
Consider various perspectives on current controversies in any vasculitis
Bernhard Hellmich, MD, Professor of Medicine
University of Tübingen
Medius Kliniken, Department of Internal Medicine,
Rheumatology & Immunology
Kirchheim unter Teck, Germany
Lillian Barra, MD, MPH, FRCPC
Associate Professor
Schulich School of Medicine and Dentistry
University of Western Ontario
London, ON Canada
Update from the FVSG (French Vasculitis Study Group)
French Presentation: February 3rd, 2023 12:00-1:00pm EST || English Presentation: February 14th, 2023 12:00-1:00pm EST
After attending this event, participants will be better able to;
-
Evaluate the duration and regimens for remission-maintenance in ANCA-associated vasculitis;
-
Consider the use of rituximab in Eosinophilic granulomatosis with polyangiitis (EGPA).
Benjamin Terrier, MD, PhD
Internal Medicine
National Referral Center for Autoimmune Diseases
Hôpital Cochin, Paris, France
*French Presentation
*English Presentation
Vasculitis Updates from ACR and the ASN
Thursday December 14, 2023, 7:00-8:00pm EST
After attending this event, participants will be better able to:
-
Identify the key points presented at the ACR and the ASN and incorporate these into clinical practice;
-
Utilize new evidence for the management of vasculitis;
-
Consider various perspectives on current updates in vasculitis.
Bryce Barr, MD
Associate Professor
University of Manitoba
Winnipeg, MB
Stephanie Garner, MD, MSc, FRCPC
Clinical Assistant Professor
University of Calgary
Calgary, AB
Lillian Barra, MD, MPH, FRCPC
Associate Professor
Schulich School of Medicine and Dentistry
London, ON
Recommendations for the Management of EGPA
Thursday March 14, 2024 1:00-2:00pm EST
After attending this event, participants will be better able to:
-
Differentiate between EGPA and other disorders; how to develop the diagnostic work up.
-
Identify the main patient characteristics that guide treatment in EGPA (FFS, other clinical manifestations)
-
Consider the main treatment approaches for severe vs non severe EGPA and for newly diagnosed vs relapsing disease.
-
Identify the differences between the European and US EGPA guidelines.
Christian Pagnoux, MD, MSc, MPH
Associate Professor, Founder and Vice-Director of CanVasc
Mount Sinai Hospital
Vasculitis Clinic, Division of Rheumatology
Department of Medicine, University of Toronto
Augusto Vaglio, MD, PhD
Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Italy
Nephrology and Dialysis Unit, Meyer Children’s Hospital, Florence, Italy
Tools for Improving the Diagnosis of GCA
Monday May 27, 2024
After attending this event, participants will be better able to:
-
Review the role for temporal artery biopsy, ultrasound, and MRI in Giant cell arteritis.
-
Discuss challenges in diagnosing Giant cell arteritis.
-
Summarize new and emerging approaches for diagnosing Giant cell arteritis.
Jean-Paul Makhzoum, MD MSc
FRCPC FACP
Associate Professor
University of Montréal
Mats Junek MD MSc PhD(c) FRCPC
Rheumatologist
McMaster University
Michael Seidman, MD PhD
Assistant Professor
University of Toronto
Update from the American College of Rheumatology Convergence 2024
December 3, 2024 7:00-8:00pm EST
After attending this event, participants will be better able to:
-
Identify the key points in vasculitis presented at the ACR and discuss how to incorporate these into clinical practice (or not [yet])
-
Utilize new evidence for the management of vasculitis
-
Consider various perspectives on current updates in vasculitis
Christian Pagnoux, MD, MSc, MPH
Associate Professor, University of Toronto
Toronto, ON
Hugues Allard-Chamard, MD, PhD, FRCPC
Assistant Professor
Université de Sherbrooke
​
Marie Clements-Baker, MD
Associate Professor
Queen’s University
Kingston, ON
Reducing Corticosteroid Exposure in ANCA Vasculitis: EGPA
Tuesday March 25, 2025 7:00-8:00 PM EST
Part 1 of the 2025 CanVasc webinar series.
After attending this event, participants will be better able to:
-
Appreciate the role of glucocorticosteroids in EGPA and the toxicity related to steroids
-
Consider the evidence of anti-IL5 biologics as steroid-sparing therapies in EGPA
-
Relate steroid sparing to eosinophil suppression
-
Compare the effects of steroids vs biologics on Vasculitic vs non-Vasculitic components of EGPA
Parameswaran Nair
MD, PhD, FRCP, FRCPC, FCAHS
Professor of Medicine
McMaster University
Nader A. Khalidi, MD, FRCPC
Professor of Medicine
McMaster University
​Update on Pediatric Vasculitis
Part 2 of the 2025 CanVasc webinar series.
​
Missed Part One?
Click on the adjacent tab titled “ANCA Vasculitis: EGPA” to catch up.
